RJB is a consultant to Immucor, Inc., and Cerus Corp. The authors attest that they have no conflicts of interest with respect to this study.
Bacterial contamination of whole blood–derived platelets: the introduction of sample diversion and prestorage pooling with culture testing in the American Red Cross
Article first published online: 24 JUL 2008
© 2008 American Association of Blood Banks
Volume 48, Issue 11, pages 2348–2355, November 2008
How to Cite
Benjamin, R. J., Kline, L., Dy, B. A., Kennedy, J., Pisciotto, P., Sapatnekar, S., Mercado, R. and Eder, A. F. (2008), Bacterial contamination of whole blood–derived platelets: the introduction of sample diversion and prestorage pooling with culture testing in the American Red Cross. Transfusion, 48: 2348–2355. doi: 10.1111/j.1537-2995.2008.01853.x
- Issue published online: 3 NOV 2008
- Article first published online: 24 JUL 2008
- Received for publication April 25, 2008; revision received May 24, 2008; and accepted May 26, 2008.
BACKGROUND: Bacterial sepsis following whole blood–derived platelet (WBP) transfusion has remained a substantial patient risk, primarily due to a lack of practical and effective means to limit or detect bacterial contamination. We describe the risk of reported septic reactions to WBPs and the introduction of prestorage-pooled whole blood–derived platelets (PSPs) collected using initial sample diversion and cultured for bacterial contamination.
STUDY DESIGN AND METHODS: Product qualification and quality control (QC) testing with the Acrodose PL system (Pall Medical) were evaluated in four regional blood centers. Bacterial contamination risk was assessed by review of reported septic transfusion reactions to WBPs and by aerobic QC culture of leukoreduced PSPs utilizing automated microbial detection system cultures (BacT/ALERT 3D, bioMérieux).
RESULTS: Before implementing PSPs (January 2003-December 2006), we distributed 2,535,043 WBP units and received 20 reports of septic reactions including 2 fatalities (7.9 per million [1:126,752] reactions and 0.79 per million [1:1,267,522] fatalities). In October 2006, PSPs were effectively implemented with a product qualification success rate of 99.6 percent and a mean yield of 4.0 × 1011 platelets (PLTs) per pool. Whole blood collection sets with sample diversion technology were introduced during the operational trial and decreased the rate of confirmed-positive bacterial culture of PSPs from 2111 (1:474) to 965 (1:1036) per million (odds ratio, 0.46; 95% confidence interval, 0.22-0.95). No septic reactions to PSPs were reported (25,936 PSP units distributed).
CONCLUSION: Sample diversion and bacterial culture are effective methods to reduce bacterial risk with WBP transfusion. Bacterial contamination of PSPs was assessed at 5.8-fold our current rate for apheresis PLTs utilizing comparable culture protocols.